Join to view full profile
55 Fruit StreetBoston, MA 02114
Phone+1 617-724-4000
Dr. Sullivan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ryan Sullivan is an oncologist based in Cambridge, MA, specializing in hematologic oncology and melanoma, including melanoma and cutaneous malignancies. He completed his medical education at Uconn School Of Medicine in 2001, followed by a residency in internal medicine at Mount Auburn Hospital and a fellowship in hematology and medical oncology at Beth Israel Deaconess Medical Center. Dr. Sullivan has contributed to several publications, focusing on melanoma and immunotherapy, and has been involved in various clinical trials exploring treatments for BRAF-mutant melanoma and other advanced cancers.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Mount Auburn HospitalResidency, Internal Medicine, 2001 - 2004
Uconn School Of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2004 - 2027
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2016
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2016
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2016
Clinical Trials
Publications & Presentations
PubMed
- Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study.Andrea Boutros, Janet McKeown, Roger Olofsson Bagge, Lars Ny, Jan Mattsson
Journal for Immunotherapy of Cancer. 2026-10-07 - Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy.Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, Tyler Aprati, Giuseppe Tarantino
Med. 2026-09-11 - 4 citationsIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.Adnan Khattak, Matteo S Carlino, Tarek Meniawy, George Ansstas, Matthew H Taylor
Journal of Clinical Oncology. 2026-09-10
Journal Articles
- Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic MelanomaGenevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
- Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic MelanomaRyan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
Lectures
- Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing — Immunotherapy Sequencing...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Forestalling BRAF-Inhibitor Resistance in a Shocking WayRyan Sullivan, MD, Clinical Cancer Research
https://www.doximity.com/articles/250420a4-97de-460d-87c1-5ef5e3415ddc
UpToDate, Wolters Kluwer Health - 2013-04-10
Authored Content
- Forestalling BRAF-Inhibitor Resistance in a Shocking WayJuly 2018
- Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
- Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study☆February 2018
Press Mentions
A ‘Paradigm Shift’: Moderna Cancer Vaccine Results Could Herald New World of TreatmentAugust 19th, 2026
“Bonus” from mRNA Vaccines: Cancer Patients Receiving Them Before Immunotherapy May Live LongerOctober 28th, 2025
As mRNA Falls Out of Favor for HHS, Are Cancer Vaccines Next?August 7th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
